Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study

H. Léna, Laurent Greillier, Claire Cropet, Olivier Bylicki, I. Monnet, Clarisse Audigier-Valette, L. Falchero, A. Vergnenègre, Pierre Demontrond, Margaux Geier, Florian Guisier, S. Hominal, Chrystèle Locher, R. Corre, C. Chouaïd, Charles Ricordel, Hervé LENA, Alain VERGNENEGRE, Chrystèle LOCHER, Margaux GEIER, Thomas PASCAL, Laurent GREILLIER, Pierre FOURNEL, Maurice PEROL, Lionel FALCHERO, Stéphanie MARTINEZ, Nicolas PALEIRON, Florian GUISIER, Gwenaëlle LE GARFF, Hélène DOUBRE, Stéphane HOMINAL, Jean-Bernard AULIAC, Marie WISLEZ, Gonzague DE CHABOT, Pierre-Alexandre HAUSS, Isabelle MONNET, Pascal ASSOULINE, Cécile DUJON, Hervé LE FLOCH, Pierre DEMONTROND, Régine LAMY, Géraldine FRANCOIS, Marie MARCQ, Clarisse AUDIGIER-VALETTE, Anne MADROSZYK-FLANDIN, Jacky CREQUIT, Roland SCHOTT, Samir ABDICHE, Marielle SABATINI, Thierry CHATELLIER, Romain CORRE, Jacques LE TREUT